Energy intake as a short-term biomarker for weight loss in adults with obesity receiving liraglutide: A randomized trial.

ABSTRACT:

Background and objective

Obesity is a chronic disease associated with many serious comorbidities. Pharmacologic therapies are approved for the treatment of obesity; however, short-term biomarkers to predict weight loss are not well understood. This study aimed to determine the ability of single-meal energy intake (EI) to predict weight loss in participants with obesity treated with liraglutide.

Methods

In this randomized, double-blind, placebo-controlled study, participants received subcutaneous liraglutide (titrated to 3.0 mg/day) or placebo once daily, with inpatient assessments at baseline and weeks 3 and 6. The primary endpoint was change from baseline (CFB) in EI during consecutive ad libitum lunch meals at weeks 3 and 6. Secondary endpoints included CFB in 24- and 48-h

SUBMITTER: Saxena AR 

PROVIDER: S-EPMC8170575 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature